NOVEL PIPRAZINE CARBOXAMIDES

Abstract: The present invention concerns novel compounds of general formula (I) wherein R1 and R2 are the same or different and selected from hydrogen or lower alkyl; wherein Ar are the same or different and selected from (II) and (III) wherein R3 is halogen or hydrogen. n is 2 or 3, X is nitrogen or methine. When X is nitrogen Y is methylene. When X is methine Y is selected from nitrogen or oxygen. A is selected from the carboxylic derivatives (IV) and (V) wherein R4 and R5 are the same or different and selected from hydrogen, alkyl, cycloalkyl or aryl. Z is selected from sulfur or oxygen. R6 is selected from (VI) and (VII) wherein m is 1, 2, 3 or 4. R7 is selected from hydrogen or lower alkyl, and the pharmacologically active salts thereof. The new compounds are useful for treating mental disorders.

Description: NOVEL PIPRAZINE CARBOXAMIDES Background There is an urgent need for efficient drugs in the treatment of mental disorders which are more effective and which have fewer side effects than the drugs in clinical use today. Antipsychotic drugs in current use produce a range of troublesome extrapyramidal movement disorders (e.g. acute dystonic reactions and tardive dyskinesia) and are poor in ameliorating the negative symptoms (e.g. restricted or blunted emotional arousal) of schizophrenia. The main disadvantage of the antidepressants is that they fail to alleviate depression in 30 to 40 % of patients. Anxiolytics are commonly associated with addictive properties. Prior Art Various piperazine derivates pharmacologically active in the central nervous system are known in the art. Some representative examples can be mentioned. The US patent 4308387 discloses amperozide which has shown useful anti¬ psychotic properties in clinical investigations. Amperozide has a limbic profile of action. Amperozide Description of the invention According to the invention there are provided novel compounds having the general formula (I). wherein Ar are the same or different and selected from wherein R3 is halogen or hydrogen. R] and R2 are the same or different and selected from hydrogen or alkyl; n is 2 or 3, X is nitrogen or methine When X is nitrogen Y is methylene. When X is methine Y is selected from nitrogen or oxygen; A is selected from the followine carboxvlic derivatives: wherein R4 and R5 are the same or different and selected from hydrogen, alkyl, cycloalkyl or aryl. Z is selected from sulfur or oxygen. R^ is selected from 7 — N >(CH 2 )m wherein m is 1, 2, 3 or 4. R7 is selected from hydrogen or lower alkyl. And the pharmacologically active salts thereof. Used in the foregoing definitions the term lower alkyl is meant to include straight and branched, saturated and unsaturated hydrocarbon groups having from 1 to 5 carbon atoms; the term cycloalkyl is meant to include cyclic, saturated and unsaturated hydrocarbon groups have from 3 to 8 carbon atoms, the term lower alkoxy is meant to include straight or branched, saturated or unsaturated alkoxy groups having from 1 to 5 carbon atoms; the term halogen is meant to include fluoro, and bromo. The compounds of formula (I) have basic properties and, consequently, they may be converted to their therapeutically active acid addition salts by treatment with appropriate acids; e.g. inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric and phosphoric acid, or organic acids such as acetic, propanoic, glycolic, lactic, malonic, oxalic, succinic, fumaric, taitaric, citric and pamoic acid. Conversely, the salt form can be convened into the free base form by treatment with alkali. The compounds of formula (I) and their pharmaceutically acceptable salts have valuable pharmacological propeπies. making them useful for the treatment of mental disorders such as psychoses, depression, anxiety and drug abuse. Stress and anxiety in animals can also be treated. The compounds of the present invention show psychotropic properties. They have found to be selective 5-HT2 antagonists. Methods of preparation The compounds having the general formula (I) may be prepared by conventional methods. Method 1 II πi A compound of formula (II), wherein Ar, X and Y are as previously defined and L is a suitable leaving group such as halogen and alkyl- or arylsulfonate is reacted with a compound of formula (III) wherein R- , R2, A and n are as defined previously. The reactions may be carried out using standard N-alkylating procedures. Method 2 IV V VI A compound of formula TV, wherein Ar, Ri , R2, X, Y, Z and n are as previously defined is reacted with a compound of formula V, VI, wherein R4, R5, R5 and Z are as previously defined and L is a suitable leaving group. Method 3 0=C=N— R A VII A compound of formula IV is reacted with a compound of formula VII wherein R4 is as previously defined. Method 4 VIII IX A compound of formula VIII, wherein Ar is as previously defined is reacted with a compound of formula IX, wherein n and A are as previously defined. L is hydroxy or a leaving group. Method 5 A compound of formula X wherein Ar, n, K~ and R4 are as previously defined is reacted with a compound of formula V or VI to yield a product of formula XI. XI wherein Ar, n, R R2 and A are as previously defined. The compound XI is reduced to yield a compound of formula XII, E SHEET xπ Wherein Ar, R3, R4, n and A are as previously defined. Method 6 xm A compound of formula m wherein Ar, X, Y, Rl, R2 and Z are as previ¬ ously defined is reacted with a secondary amine to yield a product described by formula (I). Method XIV XV A compound of formula IV is reacted with triphosgene (XIV) to yield a product of formula (XV), wherein Ar, n, X, Y, R- and R2 are as previously defined, which is reacted with a secondary amine to yield a product described by formula (I). Examples The following examples are intended to illustrate but not limit the scope of the invention, although the compounds named are particular interest for our intended purposes. These compounds have been designated by a number code, a:b, where a means the number of the example, wherein the preparation of the compound in question is described, and b refers to the order of the compounds prepared according to that example. Thus, compound 1 :2 means the second compound prepared according to example 1. The structures of the compound are confirmed by NMR, masspectra and elementary analysis. When melting points are given, these are uncorrected. Example 1: 1 l-{3-[Bis(p-fluorophenyl)amino] propy.}-N-ethy.-4-piperazine-carboxamide hvdroch.oriάe. 4.7 g (0.3 mol) of N-ethylpiperzinecarboxamide, 13.4 (0.036 mol) of 3-[Bis- (p-fluorophenyl)amino]propyiiodide and 5 g (0.060 mol) of NaHCO3 were refluxed for 48h in ethanol BSTITUTE SHEET After cooling, the reaction mixture was filtrated. Evaporation of the solvent yielded the crude base. 3.2 g of the free base was dissolved in 40 ml of diethyl ether. The hydrochloride was precipitated with excess of hydrochloric acid in ethanol. Recrystallisation in 2-butanone yielded 2.7 g of the title compound (1:1) m.p. 164-165°C. Example 2: 1 4-{2-[(4,4'Difluorobenzhydryl)oxy}-ethyI]-N-n-octyl-l-piperazine- carboxamide hydrochloride 5.6 g (0.017 mol) 2-[(4,4'Difluorobenzhydryl)oxy]ethyl piperazine, 4.5 g (0.018 mol) phenyl-octylcarbamate and 2.8 g of potassium carbonate was stirred and refluxed together with 60 ml of toluene for about 1 h. The reaction mixture was filtrated. The filtrate was washed three times with water and then with brine. The organic layer was dried over sodium sulphate and filtered. The solvent was removed from the filtrate by evaporation to yield an oil. 6.5 g of the oil was dissolved in 70 ml of ethyl acetate. The hydrochloride was precipitated with excess of hydrochloric acid in ethanol. Recrystallisation from isopropanol/ether yielded 5.3 g of the titled compound (2: 1), m.p. 171-172°C. In essentially, the same method was used to prepare the following compound. 2:2 l-[2-[(4,4'-Difiuoroberj^hydryl)amino]ethyl]-4-(N-isopropylcarbamoyl)piperazine 2.25 hydrochloride m.p. 192-193 0 C EET Example 3 : 1 4-[2-[(4,4'Difluorobenzhydryl)oxy]-ethyl]-N-ethyl-l-piperazinecarboxamide hydrochloride. 5 g 2-[(4,4'Difluorobenzhydryl)oxy]-ethyl-piperazine and 100 ml of ether were placed in a three-necked flask. 1.1 g ethylisocyanate dissolved in 20 ml of ether was added drop by drop to the flask. The reaction mixture was stirred for 2 h at room temperature. The solvent was evaporated. The residue was dissolved in ether. The hydrochloride was precipitated with excess of hydrochloride in ethanol. Recrystallisation from iso-propanol yielded 4.5 g of the title compound (3:1) , m.p. 191-192°C. In essentially, the same method was used to prepare the following compounds. 3:2 4-[2-[(4,4'Difluorobenzhydryl)oxy]-ethyl]-N-cyclohexyl-l-piperazine- carboxamide hydrochloride m.p. 199-200°C 3:3 4-[2-[(4,4 'Difluorobenzhydryl)oxy]-ethyl]-N-phenyl- 1 -piperazine- carboxamide hydrochloride m.p. 211-212°C 3:4 4-[2-[(4.4'Difluorobenzhydryl)oxy]-ethyl]-N-methyl-l-piperazine- thiocarboxamide hydrochloride m.p. 193-194°C 3:5 l-[3-(N-4-pyridyl-4-fluoroanilino)propyl]-N-ethyl-4-piperazine- carboxamide dioxalate m.p. 172-173°C 3:6 l-[3-( -pyridyl-4-fluoroanilino)propyl]-N-phenyl-4-piperazinecarboxamide difiimarate m.p. 151-155°C 3 :7 l-[3-(N,N-Di(p-fluorophenyl)arnino)propyl]-N-cyclohexyl-4-piperazinecarboxarnide hydrochloride, hydrate 167- 70°C TUTE SHEET 3:8 l-[3-(N,N-Di(p-fluorophenyl)amino)propyl]-N-phenyl-4-piperazinecarboxamide hydrochloride. hernihydrate 187-190°C 3:9 l-[3-(N,N-Di(p-fluorophenyl)ammo)propyl]-N-phenyl-4-pipera-_inethiocarboxamide 1.5 hydrochloride m.p. l87-188°C 3: 10 l-[3-(N-pyridyl-4-fluoroanilino)propyl]-N-cyclohexyl-4-pipera_ necarboxamide difumarate m.p. 175°C (dec.) Example 3b: 1 4-{2-[(4,4-Difluorobenzhydryl)oxy]ethyl}-l-piperazinecarboxamide hydrochloride. A solution of 4-{2-[(4,4-Difluorobenzhydryl)oxy]ethyl}piperazine, (4.0 g 0.012 mol) in 20 ml glacial acetic acid was cooled to 0°C at which time 3 g (0.036 mol) of potassium cyanate dissolved in 20 ml water was added. The resulting solution was stirred at room temperature for 24 hours, and then diluted with 100 ml of water. 20 % aqueous sodium bicarbonate solution was added to reach pH 7 and then extracted three times with 200 ml of ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulphate and the solvent was evaporated. The residue 4 g (0.011 mol) was purified by silica gel column chromatography (dichloromethane: methanol 10: 0.9 ) and the pole fractions of interest were combined and concentrated, 3 g of an oil was obtained. After adding of 20 ml of ethanol and cooling, the substance solidified. The solid formed was collected by filtration and washed with two 20 ml portions of cold ethanol. The solid was dissolved in ether and 5-N HC1 in ethanol was added. A white solid was obtained by recrystallisation from ethanol:ether. 3 g of the title compound (3b: 1) were obtained m.p 116-119° C. Example 4: 1 4-{2-[(4.4'-Difluorobenzhydryl)oxy]ethyl}-N-methyI-l-piperazinecarboxamide hydrochloride 3.7 g (0.020 mol) of l-(2-hydroxoethyl)-N- methyl- 1-piperazinecarboxamide and 2.4 g (0.010 mol) of 4-fluorobenzhydrylchloride were stirred at 165-170°C (temperature of oil bath) for 45 min. under nitrogen. After cooling, 60 ml of water and 60 ml of toluene were added to the reaction mixture. The phases were separated. Evaporation of the organic solvent yielded the crude base which was purified by flash chromatography and isolated as an oil 2.0 g of the free base was dissolved in 20 ml of ether. The dihydrochloride was precipitated with excess of hydrochloric acid in ethanol. Recrystallisation in isopropanohdiethylether 3:1 yielded 1.5 g of the titled compound (4:1), m.p.202-203°C Example 5: 1 l-{2-[(4,4 ' Diπuorobenzhydryl)amino]ethyl}-N-cyclohexyl-4-piperazinecarboxamide 2.25 hydrochloride 3.2 g (0.01 ml) of l-[2.[(4,4 ' -Difluorobenzhydrylidene)amino3ethyl] piperazine and 80 ml of ether were placed in a three-necked flask. 1.4 g (0.01 ml) cyclohexylisocyanate dissolved in 20 ml of ether was added drop by drop to the flask. The reaction mixture was stirred for 2 h at room temperature and crystals were formed. The product was then filtered off. 2.2 g (0.05 ml) of the crystals was dissolved in 20 ml of methanol and 1.0 g (0.03 ml) of NaBH4 were added and refluxed for 1 h. After cooling, the solvent was evaporated and the residue was dissolved in water and ether. The ether layer was washed three times with water and dried. The hydrochloride was precipitated with hydrochloric acid in ethanol. Recrystallisation from isopropanol yielded 1.8 g of the titled compound (5: 1) m.p. I96-197°C. In essentially, the same method was used to prepare the following compounds. 5.2 l-[2-[(4,4'-Difluorobenzhydryl)amino]ethyl]-4-(N-butylcarbamoyl) piperazine 2.25 hydrochloride m.p. 165-167°C l-[2-[(4,4-Difluorober_zhydιyl)amino]ethyl]-N-phenyl-4-piperazinethiocarboxamide m.p. 133-134°C. Example 6: 1 l-{2-[(4,4'-Difluorobenzhydryl)oxy]ethyl}-(4-morpholino-carbonyl)piperazine hydrochloride 10 g of 4-[2-[(4,4 ' -Difluorobenzhydryl)oxy]ethyl]-p-nitrophenylpiperazinecarbamate was heated at 140°C together with 20 ml of morpholine for 12 h. The excess of morpholine was evaporated. The residue was dissolved in ether and washed with brine. 10% NaOH, brine. The solvents were evaporated and the crude base was obtained as an oil. The oil was dissolved in ether and the hydrochloride was precipitated by hydrochloric acid in ethanol. Recrystallisation from methanol/acetone 1: 10 yielded 8.0 g of the titled compound (6:1), m.p. 208-209°C. In essentially, the same method was used to prepare the following compounds 6:2 l-[2-[(4,4 ' -Difluorobenzhydryl)oxy]ethyl]-4-(pyrrolidino-carbonyl)piperazine hydrochloride m.p. 170-171°C 6:3 l-[2-[(4,4 ' -Difluorobenzhydryl)amino]ethyl]-4-(4-methylpiperidinocarbonyl) piperazine 2.5 hydrochloride m.p. 219-221°C 6:4 l-[2-[(4,4 ' -Difluorober_zhydryl)ar_ιino]ethyl]-4-(N,N-dipentylcarbamoyl)piperazine 2.5 hydrochloride m.p. 113-115°C 6:5 l-[3-(N,N-Di(p-fluorophenyl)amino)propyl]-N,N-diethyl-4-piperazinecarboxaι__ide hydrochloride m.p. 141-142°C Example 7: 1 l-{2-[(4,4'-Difluorobenzhydryl)oxy]ethyl}-4-(N,N-diethylcarbamoyl)piperazine hydrochloride.. A solution of 5 g (0.015 mol) of l-[2-[(4,4 ' -Difluorobenzhydryl)oxy]ethyl]piperazine, 50 ml toluene and 3 ml (0.02 mol) triethylamine was added dropwise to a solution of 1.5 g (0.005 mol) triphosgene in 100 ml toluene at 5-10°C for lh. The mixture was allowed to stand at room temperature for 16 h and then washed with 1-N NaOH and water, dried over sodium sulphate. Evaporation of the solvent yielded the crude base as an oil. The oil was dissolved in ether and the hydrochloride was precipitated with excess of hydrochloric acid in ethanol. Recrystallisation from ethyl acetate: 2-butanone (3: 1) yielded 2.5 g of the title compound (7:1) m.p. 158-160°C (dec). In essentially, the same method was used to prepare the following compound. 7:2 l-[2-[(4,4'-Difluorober-zhydryl)oxy]ethyl]-4-(N,N-dipropyicarbamoyl)piperazine hydrochloride m.p. 125-127°C Example 8 Test 1. Affinity to 5-HT2 receptors The binding assay is carried out essentially as described by Leysen et al. (Mol. Pharmacol. 21, 301-14, 1982) using 3 H-ketanserin as iigand. l est 2. Affinity to D2-receptors. The binding assay is carried out essentially as described by Leysen et al. (Mol. Pharmacol. 21, 301-14, 1982) using 3 H-spiroperidol as Iigand. Table 1 5 Compound 5-HT2 E Kj fnM Kj fnM) 3: 1 60 >10000 3:4 20 1600 10 6:2 15 1780 Amperozide 17 540 The compounds listed in Table 1 are not given for purpose of limiting the invention thereto but only to exemplify the useful pharmacological activities of compounds within the scope 15 of formula (I). Example 9 20 The following formulations are representative for all of the pharmacologically active compounds of this invention. Example of a suitable capsule formulation: -> - 30 In case of higher amounts of active ingredients, the amount of lactose used may be reduced. 35 Example of a suitable tablet formulation Solutions for parenteral applications by injection can be prepared in a aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substance preferably in a concentration of from about 0.5% to about 5% by weight. These solutions may also contain stabilising agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules.

Claims: CLAIMS 1. Novel compounds having the general formula (I) wherein Ar are the same or different and selected from wherein R3 is halogen or hydrogen. R- and R2 are the same or different and selected from hydrogen or lower alkyl, n is 2 or 3, X is nitrogen or methine When X is nitrogen Y is methylene. When X is methine Y is selected from nitrogen or oxygen. A is selected from the followins carboxylic derivatives. Wherein R4 and R5 are the same or different and selected from hydrogen, alkyl, cycloalkyl or aryl. Z is selected from sulfur or oxygen. R is selected from Λr — N O l (CH 2 )m \ / wherein m is 1, 2, 3 or 4. R7 is selected from hydrogen or lower alkyl, and the pharmacologically active salts thereof. 2. Compounds according to claim 1 wherein n is 2. 3. Compounds according to claim 1 or 2, wherein R- and R2 are hydrogen. 4. Compounds according to claim 3 wherein X is methine. 5. Compounds according to claim 4 wherein Y is oxygen. 6. Compounds according to claim 5 wherein R4 and R5 are selected from hydrogen or lower alkyl. 7. Compounds according to claim 5 wherein R^ is pyrrolidine. 8 A method of preparing compounds having the general formula (I) wherein Ar are the same or different and selected from wherein R3 is halogen or hydrogen. Rj and R2 are the same or different and selected from hydrogen or alkyl; n is 2 or 3 X is nitrogen or methine When X is nitrogen Y is methylene. When X is methine Y is selected from nitrogen, oxygen or sulfur. A is selected from the following carboxylic derivatives. wherein R4 and R5 are the same or different and selected from hydrogen, alkyl. cycioalkyl or aryl. Z is selected from sulfur or oxygen. R>5 is selected from wherein m is 1, 2, 3 or 4. R7 is selected from hydrogen or lower alkyl, and the pharmacologically active salts thereof wherein a compound having the general formula (II) Ar \ X — γ_(CH 2 ) 2 — L Ar II wherein _ r, X and Y are as defined above and L is a leaving group, is reacted with a compound having the general formula (HI) R^CH^n in wherein R- , R2, n and A are as defined above or wherein a compound having general formula (IV) IV wherein Ar, R- , R2, X, Y and n are as previously defined, is reacted with a compound having the formula (V) or (VI). V VI wherein Z, R4 and R5 are as previously defined and L is a leaving group. or wherein compound IV, defined as above, is reacted with a compound having the formula VII 0=C=N— R 4 VII wherein R4 is as previously defined. or wherein a compound having the general formula VIII vm wherein Ar is as previously defined, is reacted with a compound of formula IX and L is a leaving group or a hydroxyl. DC wherein Ri , R2, n and A are as previously defined. X N-R 4 R 6 R 5 V VI or wherein compound of formula X wherein Ar, n, R3 and R4 are as previously defined is reacted with a compound offormula V or VI to yield a product of formula XI. XI wherein Ar, n, Ri, R2 and A are as previously defined. The compound XI is reduced to yield the desired product a compound offormula XII. xπ Wherein Ar, R3, R4, n and A are as previously defined. xm or wherein a compound offormula XHt, described above, wherein Ar, X, Y, Rl, R2 and Z are as previously defined is reacted with a secondary amine. XIV XV or wherein compound offormula IV described above is reacted with triphosgene (XIV) to yield a product offormula (XV), wherein Ar, n, X, Y, Rjand R2 are as previously defined, which is reacted with a secondary amine. 9. Pharmaceutical compositions containing as an active ingredient one or more of the compounds having the general formula (I), preferably together with a pharmaceutically acceptable carrier and, if desired, other pharmacologically active agents. 10. A method of treating a living body suffering from a mental disorder, which comprises the step of administering to said living animal body a compound having the general formula (I).

Inventors: ABRAMO LISBETH, BRODSZKI MARTIN, LUNDSTEDT TORBJOERN, NORDVI CURT, OLSSON KNUT GUNNAR, ABRAMO, LISBETH, BRODSZKI, MARTIN, LUNDSTEDT, TORBJOERN, NORDVI, CURT, OLSSON, KNUT, GUNNAR
Applicants: ABRAMO LISBETH, BRODSZKI MARTIN, KABI PHARMACIA AB, LUNDSTEDT TORBJOERN, NORDVI CURT, OLSSON KNUT GUNNAR
Application year: 1993
Main classification: C07D241
IPC codes: A61K31, A61P25, C07D213, C07D295